Search Results

Techdow USA Inc., a wholly owned subsidiary of Hepalink USA Inc., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd., an integrated company engaged in the Development, Manufacturing and Licensing of pharmaceuticals, are pleased to announce the signing of a Licensing, Supply and Distribution agreement regarding the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® for injection in the US market.

Inventiva and Sino Biopharm, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., announce that CTTQ received Investigational New Drug approval from the Chinese National Medical Products Administration on May 22nd 2023, and can now initiate the clinical development of Inventiva’s lead compound lanifibranor in mainland China.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced the appointment of Tai-An Lin, Ph.D., as its Chief Scientific Officer.

SEED Therapeutics, a BeyondSpring subsidiary and global research company focused on harnessing and engineering “molecular glues,” a targeted protein degradation platform to attack previously believed undruggable targets, announced that it has appointed Jackson Tai to its Board of Directors.

Tay Therapeutics, focused on developing small molecules for oncology and severe inherited diseases, today announced that it has entered into an exclusive license agreement with VYNE Therapeutics Inc. (Nasdaq: VYNE),

Inventiva (Euronext Paris and Nasdaq: IVA) and Chia Tai-Tianqing Pharmaceutical Group Co., Ltd (“CTTQ”), a subsidiary of Sino Biopharm, have entered into a licensing and collaboration agreement (the “Agreement”) to develop and commercialize lanifibranor, Inventiva’s proprietary compound, for the treatment of non-alcoholic steatohepatitis (“NASH”) and potentially other metabolic diseases in mainland China, Hong Kong, Macau and Taiwan (“Greater China”).

Myrtelle Inc. today announced that updated positive data in its open-label Phase 1/2 First-in-Human (FIH) clinical trial for Canavan disease (CD) using the Company’s recombinant adeno-associated virus (rAAV) vector-based investigational gene therapy will be presented at the National Tay-Sachs and Allied Diseases Annual Family Conference, taking place in Reston, Virginia June 1-4, 2023.